HMOs Activating GPR35 to Reduce Nociception
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nociception and nociceptive sensitivity, such as analgesics, have limited efficacy and often result in side effects, necessitating the development of safe and well-tolerated interventions that can be taken chronically to manage chronic pain conditions like fibromyalgia, irritable bowel syndrome, and neuropathic pain.
Innovation Solution
The use of human milk oligosaccharides, specifically 6′-sialyllactose (6′-SL) and lacto-N-tetraose (LNT), either alone or in combination, to activate the GPR35 receptor, reducing nociception and nociceptive sensitivity through a synthetic composition or dietary management, particularly for non-infant humans.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If analgesics are used to treat nociception and nociceptive sensitivity, then pain relief is achieved, but side effects occur and efficacy is limited
Solution Approach 1:
The patent uses GPR35 receptor as an intermediary target. Instead of directly blocking pain signals or using traditional analgesics that cause side effects, the invention employs 6'-SL and LNT to activate the GPR35 receptor, which then mediates the reduction of nociception and nociceptive sensitivity through natural physiological pathways, thereby achieving pain relief without the harmful side effects of conventional medications
Solution Approach 2:
The patent changes the therapeutic parameter from using traditional analgesic drugs to using human milk oligosaccharides (6'-SL and LNT). This parameter change shifts the mechanism of action to receptor activation rather than direct analgesic effect, resulting in a treatment that maintains efficacy while eliminating the side effects associated with conventional pain medications
2Duration of action of stationary object
If traditional analgesic treatments are used chronically to manage chronic pain, then pain symptoms are suppressed, but medication side effects increase and tolerance develops
Solution Approach 1:
The GPR35 receptor serves as a safe intermediary that can be activated chronically without the accumulation of side effects. The patent demonstrates that long-term activation of GPR35 by 6'-SL and LNT provides sustained pain management while avoiding the tolerance and side effects that occur with chronic analgesic use, as the receptor activation follows natural physiological pathways
Solution Approach 2:
The patent employs a natural, biologically-derived compound (human milk oligosaccharides) that can be administered chronically without accumulation. These compounds are metabolized and eliminated naturally, preventing the buildup of toxic metabolites that occurs with chronic analgesic use, thereby enabling long-term pain management without chronic side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The activation of GPR35 receptors by 6′-SL and LNT provides a safe and effective means to prevent or reduce nociception and nociceptive sensitivity, as demonstrated by their synergistic action and safety profile, offering a potential solution for chronic pain management without the side effects of traditional medications.
Implementation Method 1
The activation of GPR35 receptors by 6'-SL and LNT provides a safe and effective means to prevent or reduce nociception and nociceptive sensitivity
Data Source
AI summary
The application relates to synthetic compositions and methods for preventing or reducing nociception and/or nociceptive sensitivity in a non-infant human. The human is administered a composition comprising 6′-sialyllactose (6′-SL) and/or lacto-N-tetraose (LNT).